2 results
Approved WMOCompleted
to study the safety and tolerability of HM10660A (LAPS-interferon alpha-2b), including immunogenicity, as compared to Pegasys® (PEG-interferon alpha-2a)to study the pharmacokinetics and pharmacodynamics of HM10660A (LAPS interferon alpha-2b) as…
Approved WMORecruiting
The primary objective of this study is to assess the efficacy of Triumeq versus placebo on overall survival, defined as death from any cause, in participants with ALS at 24 months or after a minimum of 212 events.